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Abstract 
We have evaluated 3 molecularly defined 
nolvneutides encoded bv encloned Plasmodium falci- 
iark ‘genes for their ability to serve as antigens for 
detecting antimalaria antibodies. The recombinant 
proteins-correspond to (i) a conserved part of 190- 
200 kDa schizont merozoite surface comnonent. (ii) 
the carboxy terminal part of the P. ‘falcip&k 
aldolase, and (iii) the 5.1 antigen. Antibodies were 
detected using enzyme-linked immunosorbent assays 
(ELBA) in a high percentage of sera from individuals 
from a malaria endemic area in The Gambia (up to 
99% for some adult groups). These results were 
further improved, especially for detection of anti- 
malaria antibodies in children, when a pool of all 3 
polypeptides (ELISA MIXT) was used as antigen. 
This ELISA MIXT improves presently available 
assays for the detection of antimalaria antibodies 
directed against asexual blood stages in respect of 
standardization, sensitivity and specificity. 
Introduction 
Qualitative and quantitative determination of spe- 
cific antibodies is important for measuring the impact 
of malaria eradication or control programmes at the 
population level, in malaria endemic areas. In the 
future antimalarial antibodies in defined areas should 
be monitored before, during and after vaccination 
trials. In developed countries, measurement ofmalar- 
ia antibodies can be employed to screen sera of blood 
donors returning from areas where malaria is en- 
demic. 
Several methods are available for the detection of 
antimalarial antibodies directed against asexual blood 
stages. Earlier tests relied on gel diffusion or on 
passive agglutination of sensitized erythrocytes. 
Other, more sensitive, tests include the indirect 
fluorescent antibody assay (IFA), radioimmunoassay 
(RIA) and enzyme-linked immunosorbent assay (EL- 
ISA) (PERRIN et al., 1984). RIA and ELISA are now 
used increasingly for epidemiological studies because 
they combine sensitivity, low cost and the possibility 
of automation. 
The major limitation of these assays is the supply of 
standardized reagents, particularly defined antigens. 
The common sources of antigens are infected red 
blood cells (NBC) collected from either infected 
human individuals or animals (VOLLER et al., 1974) 
and more recently asexual blood stages of Plasmodium 
falciparum produced by culture in vitro (SPENCER et 
Corresponding author: Dr Luc H. Perk, Centre de 
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al., 1979). The IRRC extracts contain a wide array of 
non-parasitic antigens including erythrocyte compo- 
nents and break-down products of the parasite. 
Conseauentlv, the use of total IRRC extract as antigen 
in EL&A could result in errors resulting from lthe 
high incidence of heterophile antibodies, antiglobu- 
lins or autoantibodies (ROSENBERG et al.. 1973) in the 
sera of individuals living in malaria endemic regions. 
The genes encoding a number of parasite 
polypeptides have recently been cloned and expressed 
in appropriate vectors (KEMP et al., 1986). Some 
recombinant P. falciparum components are now 
produced in high yield and purity and thus provide a 
source of molecularly defined polypeptides which can 
be used for malaria serology. 
We used the following 3 P. falciparum recombinant 
polypeptides at an identical molar concentration to 
measure antimalarial antibodies in a human popula- 
tion living in an endemic area, by means of micro- 
ELISAs. 
(i) A conserved region of the main schizont- 
merozoite surface protein termed 190L (GENTZ et al. T 
1988). 
(ii) Two-thirds of the 41 kDa protein (parasite 
aldolase) with a molecular mass of 27 kDa expressed 
in Escherichia coli (aa 112 to aa 360; U. Certa, 
unpublished results). 
(iii) An exported antigen of the erythrocytic stage 
having one or more cross-reactive epitope(s) in 
common with the circumsporozoite protein of P. 
falciparum (HOPE et al., 1985; COPPEL er al., 1985), 
designated the 5:l antigen. 
In this investigation, 3 main points are addressed: 
(i) the suitability of these recombinant polypeptides 
for the development of serological tests, (ii) the 
age-dependent development of antibody to these 
defined polypeptides and the correlation between 
antibody levels against the 3 polypeptides, and (iii) 
the effect of the pooled polypeptides on the sensitivity 
of the micro-ELISA assay. 
Materials and Methods 
Sera 
Sera samples were collected from 361 inhabitants 
(children and adults) of Keneba village in The 
Gambia during a malarial survey and stored frozen at 
-20°C until used. At the same time of sample 
collection, thick smears were also prepared for every 
individual and later examined microscopically for the 
presence of malaria parasites. All relevant informa- 
tion, including age., -sex and previous history, was 
collected for everv individual included in the studv. 
Serum samples from 5 adults in Cameroon, who 
had frequent bouts of malaria and an IFA antimalarial 
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antibody titre of 16400 constituted a pool of positive 
sera. Similarly, a pool of 5 sera collected from 
individuals never exposed to malaria and negative for 
antimalarial antibodies by IFA served as a negative 
control. 
Samples collected from 46 normal healthy blood 
donors without any past history of malaria were also 
included in the study as controls. 
Preparation of antigens for micro-ELISA assay 
Antigen 5.1. Bacterial pellets, containing the recom- 
binant‘;nalaria ntigen 5; 1, were suspended in 25 mu 
imidazole-HCl buffer. DH 7.4, to about 4x10” 
cells/ml. Deoxyribonuclease (DNase) I was added to 
5 ug/ml. Protease inhibitors, trasylol and phenyl- 
methylsulphonyl fluoride (PMSF), were added to 100 
units/ml and 1 mu respectively. Cells were broken in 
a French pressure cell at 138 000 kPa [20 000 lbfl 
in*]. Cell iysis, monitored by phase contrast micros- 
CODV. was ereater than 98%. The crude cell lvsate was 
ce&ifuged’ at 42 000 rpm for 60 min. More than 
90% of the antigen was recovered in the supernatant 
as assessed by sodium dodecyl sulphate-polyacryla- 
mide gel electrophoresis (SDS-PAGE; TAKACS, 
1979). 
Solid urea was added to the supernatant o a final 
concentration of 6 M, and the 5-l antigen was purified 
by chromatofocusing on a polybuffer exchanger 
column (PBE 94, Pharmacia), equilibrated with 
25 mM imidazole-HCl buffer, pH 7.4, containing 
6 M urea. Approximately 100 mg of protein were 
applied with polybuffer 74-HCl, pH 4? diluted 1:8 
with water and containing 6 M urea. Antigen purifica- 
tion was monitored by SDS-PAGE. Fractions con- 
taining the 5-l antigen were pooled and precipitated 
by dialysis against saturated ammonium sulphate at 
4°C. This concentration step removed not only 
polybuffer (composed of amphoteric species) but also 
eliminated bacterial pigments which co-migrated with 
antigen 5.1. The precipitated antigen was pelleted by 
centrifugation, dissolved in phosphate-buffered saline 
(PBS) c&tain&g 4 M urea; and dialysed against the 
PBS-urea buffer to remove ammonium sulnhate. The 
purity of the antigen preparation was assessed as 95% 
by SDS-PAGE. 
Mice immunized with the recombinant protein 
produced antibodies that reacted with a 22 kDa 
polypeptide on immunoblots prepared from crude 
extracts of P. falciparum merozoites (data not shown). 
Antigen 190 L. E. coli W 3110 R- paste, containing 
the recombinant malaria orotein His6190 L, was 
suspended in 25 mM imidazole-HCl, pH 7.4; con- 
taining 10% glycerol and 1 mu MgSO+ Trasylol(lO0 
units/ml) and DNase I (5 ug/ml) were added and the 
cells were broken by French pressure cell treatment at 
138 000 kPa. The homogenate was centrifuged at 
8000 rpm for 15 min to sediment debris and un- 
broken cells. Solid urea and dithiothreitol (DTT) 
were added to the supernatant fraction to a final 
concentration of 6 M and 5 mM respectively. The 
suspension was stirred magnetically for 30 mm at 4°C 
and centrifueed at 42 000 mm for 60 min to obtain 
the urea ext&t. The urea-soluble proteins were then 
fractionated by chromatofocusing as described above 
for the 5.1 antigen purification. Fractions containing 
the recombinant protein were pooled and dialysed 
against saturated ammonium sulphate at 4” for 16 h. 
For further mu&cation the nroteins DreciDitated bv 
ammonium iulphate were dissolved in, and dialyseh 
against, 0.1 M sodium phosphate buffer, pH 8.0, 
containing 6 M guanidine HCl. Dialysed samples 
were filtered through a 0.45 um pore size membrane 
and applied over a Ni++ chelate affinity column 
(GENTZ et al., 1988), equilibrated with 0.1 M sodium 
phosphate buffer, pH 8.0, containing 6 M guanidine 
HCl. The column was washed with the same buffer 
with a progressive decrease of pH from 7.0 to 6.0, 
until absorbance at 280 nm was reduced to back- 
ground level. The absorbed recombinant peptide was 
eluted with 0.2 M sodium acetate buffer, pH 5, 
containing 6 M eq. guanidine HCl. Starting with 6 g 
(wet weight) of E. coli paste, 16 mg of recombinant 
protein of more than 95% purity was obtained. 
Antigen C 41. E. coli W 3110 R- paste containing 
the recombinant malarial protein His6 C 41 was 
treated in the same way as the paste containing 190 L, 
and C 41 was ourified to >98% nuritv accordina to 
the procedure ‘described above. a - - 
Assay procedure 
The micro-ELISA tests were performed as de- 
scribed by GABRA et al. (1986), with slight modilica- 
tions, in 96-well flat bottomed polystyrene plates 
(Nunc, Denmark: PS-SH-2-69620). Briefly, the 
plates were coated with 100 ul of antigen diluted in 
bicarbonate buffer (pH 9.6, O-2 M) supplemented 
with 1 mg/litre of RIA-grade bovine serum albumin 
(BSA, Sigma Chemical Co., St Louis, Missouri, 
USA). The amount of each antigen was adjusted on 
the basis of the molecular weight of each polypeptide 
to a concentration of 20 no. After adsorption of the 
antigens overnight at 4X, the plates were washed 
twice with borate-buffered saline (BBS: 100 mu 
HsBOs, 30 mM NarB407.10 HrO, and 75 mu NaCl; 
pH 8.4) plus 0.4% Tween-20 (BBST). Non-specific 
binding &es were then saturated by incubating each 
well with 150 ul of 0.5% bovine serum albumin 
(BSA) in BBS for one hour at room temperature. The 
plates were again washed and 100 ul of dilutions of 
the test sera were added to each well, followed by 
overnight incubation at 4°C. Each serum was tested in 
duplicate at dilutions of 1: 100 and 1:2000 (in 2% BSA 
in BBST). Afterincubation, the plates were washed 6 
times with BBST. 100 ul of a I:300 dilution of goat 
anti-human immunoglobulins (h and x chain specific) 
coupled with alkalinephosphatase (Cappel Laborator- 
ies, Westchester, Pennsvlvania, USA) were added to 
each well and the plates were- left for 2 h at room 
temperature. After washing the plates, 100 ul of 
substrate solution (1 mglml of p-nitrophenylphos- 
phate in 10% diethanolamine and 0.5 mM MgClr, 
pH 9.8) were added to each well and the plates were 
incubated in the dark for 2 h. In order to minimize 
day-to-day variation in ELISA results., the incubation 
time was slightly adjusted for each mdividual plate 
with respect o positive and negative controls. Positive 
woled sera (at dilutions of l/100. l/400, l/1600 and 
i/6400) and-negative pooled sera (l/id and 11400) 
were included on each plate. The ELISA values were 
measured at h=405 nm using a multiscan photometer 
(Titerskan, Flow Laboratories, Baar, Switzerland). 
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varied considerably among the Gambian patients as 
reflected by the high standard deviation observed for 
the 3 antigens. At the I:100 dilution, a high propor- 
tion of patients (24.7% for 190 L, 454% for 5.1, and 
0.6% for C 41) had ELISA values >1*9. At a serum 
dilution of 1:2000, only 3.1 and 8.9 percent of 
patients had values > 1.9 for 190 L and 5.1 respective- 
ly, while none of the patients had values >1*9 for C 
41. 
Statistical analysis 
The results were analysed by computer using the 
Statistical Package for the Social Sciences (McGraw 
Hill, New York, NY, USA). Correlation coefficients 
(r) were calculated using Pearson’s test for pairs of 
variables. 
Results 
The age distribution of the Gambian patients in 
relation to detectable parasitaemia nd haemoglobin 
levels is presented in Table 1. Most patients in the 
O-10 years age group had a patent parasitaemia nd 
relatively low haemoglobin values. With increasing 
age, the percentage of the population with patent 
parasitaemia decreased significantly and comparative- 
ly higher haemoglobin values were observed. 
Micro-ELISA results for Gambian patients and 
blood donors using the three polypeptides as antigens 
are summarized in Table 2. Related to control blood 
donors, the Gambian patients had very high ELISA 
values for all 3 antigens. Slightly higher background 
values were observed using C 41 polypeptide com- 
pared to the other antigens. The antibody levels 
Table 1. Proportion of patients from The Gambii in different age 
groups with patent parasitaemia and hemoglobin levels 
Age group No. of Percentage with Haemoglobin level 
(Yed patients patent parasitaemia mean &SD’ (g/d0 
O-10 128 
1 l-20 70 
21-30 49 
31-+0 39 
>41 75 
‘SD=Standard deviation. 
87.4 10.76Cl.91 
60.0 12.2Ok1.37 
32.0 12.92k1.86 
30.0 12.95f2.07 
17.3 12.25k1.93 
In order to interpret results of the ELISA, baseline 
levels are rwuired. Therefore we selected as cut-off 
points the mean values measured in the control group 
of blood donors plus 2 standard deviations (SD) or 
plus 3 SD and determined for each age group of 
Gambian patients the percentage of sera with values 
higher than these cut-off points (Table 3). As 
expected, the percentage of patients with positive 
ELISAs for the 3 polypeptides increased with age. 
Fig. 1 presents the average ELISA values for the 
various age groups; the age-dependent increase in 
antibody levels for 190 L and 5.1 antigens is quite 
obvious, while there is only a slight increase in 
antibody levels to C 41. 
Correlation between antibodies directed against he 
3 antigens is shown in Table 4. A good correlation was 
observed between levels of antibodies against 190L 
and 5.1. In contrast, there was only a marginal 
correlation between antibody levels against C 41 and 
:9ia;d no significant correlation between C 41 and 
We next tried to optimize the assay in order to 
develop a sensitive assay for antimalarial antibody 
detection useful in epidemiological studies. The 
antigen source for this improved assay was a mixture 
of the 3 recombinant polypeptides. For the ELISAs, 
the antigen solutions were used at 20 nM which 
Table 2. ELISA values (absorbance at h=405 nm) in patients from The Gambia and in controls (blood 
donors) 
Antigens 
19OL 
Patients Blood donors 
Mean+ SD” Range Mean+SDa Range 
0*97+0*74 0.05-2.0 0.051+0.025 0~006-0~148 
(0.31kO.46) (0~02-2~0) (0.029_+0.023) (o-0.066) 
c41 0.56f0.36 0.07-2.0 0*145+0.043 O-072-0.264 
(0*14+0.10) (0-1~15) (0.075f0.021) (0~031-0~117) 
5.1 1.38kO.73 0.04-2.0 0~037+0~015 0~014-0~097 
(0.66+0.689) (O-2.0) (0.028+0*011) (0~009-0~068) 
“SD=Standard eviation. First line indicates results with a serum dilution of 1: 100; second line (in parentheses) 
indicates results with a serum dilution of 1:2000. 
Table 3. Proportion of seropositive cases among the Gambian patients of various age groups reacting with 
three recombinant antigens 
_II- 
Age group 19OL 
Seropositiv$yl(percent) 
5.1 
b-4 No. Mean+ZSD Mean+3SD Mean+ZSD Mean+3SD Mean+ZSD Mean+3SD 
O-10 128 93 81.3 78.9 70.3 87.5 85.2 
1 l-20 
:t 
87.1 85.7 85.7 82.9 
21-30 95.9 93.9 91.8 91.8 ;: : 
31-40 :; 97.4 92.3 92.3 89.7 100 100 
>41 97.3 94.7 90.7 89.3 98.7 96 
“Results based on mean ELBA values obtained in control group plus 2 or 3 standard deviations (SD); serum dilution l/100. 
Fii. 1. Mean ELISA values for patients of various age groups using 
different recombinant polypeptides as am@. 
Table 4. Correlation between ELISA values 
obtained with diierent antigens 
Antigens 
5.1 
Antigens 
190 L 5-l 
r=-521 
P<*OOl 
c 41 r=*148 r=.385 
lv.05 P<*OOl 
190 L “C” 41 5.1 75 150 300 
I I 
ELISA MIXT (ne/well) 
Fig. 2. Comparison of single and pooled antigens in micro-ELISA 
assay. q Mean ELISA values for patients; q control blood donors. 
Numbers over each column indicate percentage seropositivity at 
reference value of mean +3SD (serum dilution l/100). 
corresponded to 50,55 and 45 &well for 190 L, C 41 
and 5.1 respectively. For the new assay (ELISA 
MIXT) a mixture containing 40 no of each antigen 
was prepared and the wells were coated with dilutions 
corresponding to 75 ng/well, 150 ng/well and 
300 @well. To evaluate the sensitivity of the ELISA 
MIXT, 76 Garnbian sera with low ELISA values in 
one or more of the standard assays (most of them were 
children) were selected as well as 20 sera from control 
blood donors. The results of the various assays are 
shown in Fig. 2. A higher percentage of positive sera 
was detected by ELISA MIXT than by the standard 
assays. This was observed when the wells were coated 
with 75 ng of pooled antigens (in this mixture each 
single antigen was present at a lower concentration 
than in the assays based on a single recombinant 
polypeptide) and with wells coated with higher 
concentration of antigens. Only 3 sera were negative 
with the ELISA MIXT using 3 different concentra- 
tions of the pooled antigens. These 3 sera, collected 
from children, were also negative by IFA. 
Discussion 
There is a need for improved and cheap immuno- 
diagnostic tests for the qualitative and quantitative 
measurement of antimalarial antibodies. The routine 
use of such tests requires a constant and standardized 
supply of malaria ntigens. Conventional sources uch 
as infected red blood cells do not meet these 
requirements (GABRA et al., 1986; DEMEDTS et al., 
1987). Several genes coding for P. falciparum and P. 
vivux have been cloned and expressed in appropriate 
vectors. The sequences of the corresponding 
polypeptides have been determined and it has been 
shown that antibodies from individual patients with 
past malarial infection bind to some of these recom- 
binant polypeptides (BIANCO et al.,. 1988). No sys- 
tematic serodiagnostic study has been performed with 
cloned antigens with the exception of that by GABRA et 
al. (1986). 
We have investigated the suitability of 3 recom- 
binant polypeptides as molecularly-defined malaria 
antigens for immunodiagnosis. These recombinant 
antigens were selected on the basis of(i) their known 
reactivity with antibodies from humans with past 
malarial infection, (ii) the fact that their amino acid 
sequences showed little or no variation between 
different isolates of P. fukiparum (GENTZ et al., 1988; 
CERTA et al., 1988), and (iii) a high level of expression 
in their vectors. 
All the polypeptides were suitable for the detection 
of antimalarial antibodies. A very low background 
was observed using sera of individuals never exposed 
to malaria and positive reactivity was detected in 
almost all the sera of adults of a hyperendemic area 
(up to 100% positive sera in some groups of adults for 
the 5.1 antigen). Antibodies were also reliably de- 
tected in most of the sera of children. However, there 
was a clear difference in the amount of antibody 
reaction against the three recombinant polypeptides. 
Thus, levels of antibodies directed against 5.1 were 
the highest, followed by antibodies against 190 L and 
C 41. This was probably not a consequence of passive 
absorption of antibodies in zho during an acute attack 
of malaria, since differences in titre were observed for 
both the groups with a high incidence of patent 
parasitaemia (children) and a low incidence (adults). 
This may however be the reflection of better refolding 
of 5.1 and 190 L and C 41, or of the presence of more 
epitopes able to raise an antibody response on 5.1 and 
190 L. 
A clear correlation was observed between antibody 
levels directed against 5.1 and 190 L but not between 
antibodies directed against hese 2 polypeptides and C 
41. This may have been due to very high levels of 
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ant@en and red blood cell control antigen in the 
enzyme-linked immunosorbent assay for malaria. Amer- 
ican Journal of Tropical Medicine and Hygiene, 36, 
257-263. -_. __. 
Gabra, M. S., Grossiord, D., Perrin, L. H., Shaw, A. R., 
Cheuna. A. & McGregor. I A. (1986). Delined Plasmo- 
dium fikiparum antigens ‘m malaria serology. Bulletin of 
the World Health Organization, 64, 889-896. 
antibody directed against 5.1 and 190 L. When a 
mixture of the 3 antigens was used, the percentage of 
positive sera increased significantly with a selection of 
sera poorly reactive with-the individual assays. The 3 
sera negative with the ELISA MIXT were also 
negative-in the 3 assays using individual components 
and in IFA tests. In addition, the level of antibodies 
(measured by ELISA) was higher and the difference 
between negative and positive sera was greater. 
These results suggest hat an ELISA using the 3 
recombinant polypeptides, available in relatively high 
amounts, would be useful for epidemiological studies 
and would also have the advantage of genuine 
standardization (use of molecularly defined antigens). 
Additional studies are required to determine the 
ability of this assay to detect cross-reactive antibodies 
to I’: vivan epitopes, and to compare the assay 
directly with IFA; however, published data concern- 
ing anti-asexual blood-stage antibody detection in 
children (MCGREGOR 1974; VOLLER et al., 1980; 
GABRA et al., 1986) seem to indicate that the ELBA 
MIXT has a higher sensitivity. 
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